Growth Metrics

Marimed (MRMD) Preferred Stock Liabilities (2020 - 2025)

Marimed has reported Preferred Stock Liabilities over the past 6 years, most recently at $14.7 million for Q4 2025.

  • Quarterly Preferred Stock Liabilities fell 22.5% to $14.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.7 million through Dec 2025, down 22.5% year-over-year, with the annual reading at $14.7 million for FY2025, 22.5% down from the prior year.
  • Preferred Stock Liabilities was $14.7 million for Q4 2025 at Marimed, roughly flat from $14.7 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $37.7 million in Q1 2021 and troughed at $14.7 million in Q1 2025.
  • The 5-year median for Preferred Stock Liabilities is $20.5 million (2023), against an average of $26.7 million.
  • Year-over-year, Preferred Stock Liabilities surged 156.2% in 2021 and then crashed 49.64% in 2023.
  • A 5-year view of Preferred Stock Liabilities shows it stood at $37.7 million in 2021, then changed by 0.0% to $37.7 million in 2022, then crashed by 49.64% to $19.0 million in 2023, then changed by 0.0% to $19.0 million in 2024, then dropped by 22.5% to $14.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Preferred Stock Liabilities are $14.7 million (Q4 2025), $14.7 million (Q3 2025), and $14.7 million (Q2 2025).